SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-23-000627
Filing Date
2023-01-20
Accepted
2023-01-20 16:10:27
Documents
14
Period of Report
2023-01-20
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 21049
  Complete submission text file 0001654954-23-000627.txt   143603

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tenx-20230120.xsd EX-101.SCH 5720
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20230120_lab.xml EX-101.LAB 14667
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20230120_cal.xml EX-101.CAL 898
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20230120_pre.xml EX-101.PRE 9275
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20230120_def.xml EX-101.DEF 2099
8 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3611
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 23541107
SIC: 2834 Pharmaceutical Preparations